Henrietta Lacks' Estate Secures Second Major Settlement with Pharmaceutical Giant Novartis
A Decades-Long Fight for Justice
The Lacks family's struggle for accountability and compensation dates back to 1951, when Henrietta's cells were taken without her knowledge or consent during treatment at Johns Hopkins Hospital. For decades, the family lived in poverty while pharmaceutical companies profited billions of dollars from research and products developed using HeLa-derived materials.
A Rare Measure of Accountability
Civil rights attorney Ben Crump, who represents the Lacks estate, hailed the settlement as a rare measure of accountability for a decades-long injustice. 'For the family and her grandchildren, this is certainly justice because people said they would never realize any benefit or compensation from her immortal HeLa cells,' he said.
Pressure on Remaining Defendants
The Novartis settlement may intensify pressure on remaining defendants, including Ultragenyx and Viatris. Legal experts suggest that settlements with deep-pocketed companies like Novartis could shape negotiations with others and narrow the Lacks estate's path toward compensation for commercial uses of HeLa material.
A Broader Demand for Transparency and Fair Compensation
The Lacks case has forced the biomedical field to confront ethical failures around consent and race. The family's recent legal push shows a broader demand for transparency, fair compensation, and structural change in how human biological materials are used commercially.
While this settlement is a significant step towards justice for Henrietta Lacks and her family, it does not erase the ethical harms of the past. The Lacks case serves as a powerful reminder of the importance of consent, accountability, and fair compensation in the biomedical industry.
